Market Overview

Quest Diagnostics: Q3 Earnings Insights

Share:

Shares of Quest Diagnostics (NYSE:DGX) moved higher by 3% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 144.89% year over year to $4.31, which beat the estimate of $3.73.

Revenue of $2,786,000,000 rose by 42.43% from the same period last year, which beat the estimate of $2,730,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $9.00 and $10.00.

The upcoming fiscal year's revenue expected to be between $8,800,000,000 and $9,100,000,000.

How To Listen To The Conference Call

Date: Oct 22, 2020

Time: 08:30 AM

ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fir.questdiagnostics.com%2F&eventid=2628198&sessionid=1&key=9E320E5B40818C02CC55BE8899ED49A1&regTag=&sourcepage=register

Price Action

Company's 52-week high was at $131.81

52-week low: $73.02

Price action over last quarter: Up 0.73%

Company Description

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of 2,000 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

 

Related Articles (DGX)

View Comments and Join the Discussion!

Posted-In: Earnings News